Stockscreener 앱 받기
133.51
1.59%
-2.1115
전일 마감가:
$135.62
열려 있는:
$135.56
하루 거래량:
2.70M
Relative Volume:
0.40
시가총액:
$232.09B
수익:
$42.34B
순이익/손실:
$13.50B
주가수익비율:
17.32
EPS:
7.71
순현금흐름:
$6.66B
1주 성능:
+0.04%
1개월 성능:
-0.99%
6개월 성능:
+18.50%
1년 성능:
+28.72%
1일 변동 폭
$133.31
$136.41
1주일 범위
$132.93
$137.06
52주 변동 폭
$99.71
$140.84
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
ABT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
133.50 | 232.09B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
101.44 | 148.00B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
376.49 | 146.09B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
87.68 | 112.11B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
74.58 | 44.79B | 5.54B | 4.18B | 623.10M | 7.00 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Abbott Wins Dismissal of Whistleblower’s Medicare Fraud Suit - Bloomberg Law News
Abbott Declares 406th Consecutive Quarterly Dividend - marketscreener.com
Abbott Laboratories' Whole Blood Concussion Test Approved by Health Canada - marketscreener.com
Abbott Receives Health Canada Authorization for Whole Blood Rapid Test to Help Assess Suspected Concussions - PR Newswire Canada
Blood Screening Market Outlook | Key Players: Abbott Laboratories, Roche, Grifols, BioMérieux - openPR.com
Deep Venous Disease Treatment Market Key Players Analysis - openPR.com
1 Unpopular Stock that Should Get More Attention and 2 to Avoid - FinancialContent
Jim Cramer Calls Abbott “Really Excellent” - Insider Monkey
Electrophysiology Devices Market Share Leaders: Abbott, Acutus Medical, and Biosense Webster - openPR.com
Abbott Laboratories (ABT) Maintains Quarterly Dividend of $0.59 - GuruFocus
Abbott Declares 406Th Consecutive Quarterly Dividend, Payable on August 15, 2025 - marketscreener.com
Piper Sandler names Abbott, Edwards, Glaukos as top medtech catalyst picks - Investing.com Nigeria
Abbott Laboratories Keeps Quarterly Dividend at $0.59 per Share, Payable August 15 to Shareholders as of July 15 - marketscreener.com
Clinical Immunochemistry Analyzers Market projected reach USD 6.9 billion by 2034, growing at a CAGR of 4.4% | Exactitude Consultancy - GlobeNewswire Inc.
Abbott Laboratories Stock Sees RS Rating Rise To 82 - Investor's Business Daily
Stocks To Watch: Abbott Laboratories Sees RS Rating Rise To 82 - MSN
Abbott and Medtronic best positioned manufacturers in US neurology market - PharmaLive
Abbott Laboratories (NYSE:ABT) Partners With Tandem To Develop Dual Sensor Diabetes Solutions - simplywall.st
Tandem, Abbott team on insulin delivery with glucose-ketone sensor - MedTech Dive
Tandem Diabetes (TNDM) Partners with Abbott for Innovative Diabe - GuruFocus
Tandem, Abbott in deal to combine insulin delivery with glucose-ketone sensor - Seeking Alpha
Abbott (ABT) Partners with Tandem Diabetes for Advanced Diabetes Management Solutions | ABT Stock News - GuruFocus
3 Low-Volatility Stocks in Hot Water - FinancialContent
Abbott Laboratories Stock: Is ABT Outperforming the Health Care Sector? - MSN
Abbott Laboratories (ABT) Stock Dips Slightly on NYSE, Long-Term Gains Remain Solid - Daily Chhattisgarh News
Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic? - Yahoo Finance
Thousands of lawsuits over baby formula should stay where filed, court says - Reuters
Abbott (ABT) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Test Strip Market Is Booming So Rapidly 2025-2032 -Abbott - openPR.com
Abbott Announces FDA Approval Of Tendyne Transcatheter Mitral Valve Replacement System - insights.citeline.com
Abbott Laboratories Stock: Is ABT Outperforming The Health Care Sector? - Barchart.com
Goldman Sachs Adjusts Price Target on Abbott Laboratories to $153 From $147, Maintains Buy Rating - marketscreener.com
There's Been No Shortage Of Growth Recently For Abbott Laboratories' (NYSE:ABT) Returns On Capital - Yahoo Finance
Abbott Tendyne TMVR secures FDA clearance - BioWorld MedTech
Cardiac Marker Analyzer Market Is Booming WorldwideAbbott, Roche Diagnostics - openPR.com
Abbott Labs (ABT) Stock Ticks Lower: Gauging the Pulse and Future Price Points - Daily Chhattisgarh News
Abbott Benefits From Libre & Biosimilars Amid FX, Cost Headwinds - TradingView
Cancer Cell Market Projected to Witness Massive GrowthAbbott Laboratories, Novartis - openPR.com
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Pfizer (PFE) - The Globe and Mail
Abbott (ABT) Rises Higher Than Market: Key Facts - Yahoo Finance
Syphilis Market Growth Projections 2023-2032: DelveInsight - openPR.com
MotoAmerica Adopts Ground-Breaking Global Standard for Concussion Safety with Abbott's i-STAT TBI Blood Test - Sports Illustrated
Abbott reports positive dual-chamber pacemaker results - MassDevice
An Abbott competitor drops out — plus, a special circumstance for Nvidia earnings - CNBC
Abbott Laboratories (NYSE:ABT) Gains FDA Nod For Tendyne Mitral Valve System - simplywall.st
Abbott (ABT) Gains Marginal Benefit from Boston Scientific's Str - GuruFocus
Cancer Diagnostics Market Is Booming WorldwideRoche, Abbott Laboratories - openPR.com
Abbott Stock Gains Following FDA Approval of the Tendyne System - Yahoo
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.72%
0.22%
자본화:
|
볼륨(24시간):